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Abstract Use of the polymerase chain reaction (PCR) in conjunction with Southern hybridization, using probes corresponding to known phosphat- 
ase sequences, resulted in the identification of rat cDNA clones encoding a novel protein tyrosine phosphatase which was termed rPTP2E. The cDNAs 
comprise 5,543 bp and predict a polypeptide of 1175 amino acids possessing a single catalytic domain at its C-terminus. The N-terminal region of 
the deduced polypeptide displays high sequence homology to the cytoskeleton-associated proteins of the band 4.1 family. A variant form, termed 
rPTP2E1, was also identified which contains the catalytic domain only. rPTP2E and rPTP2El were expressed in various rat tissues, particularly 
abundantly in adrenal glands. The catalytic domain of PTP2E was expressed in Escherichia colt’ and was shown to possess pecific protein tyrosine 
phosphatase activity. The identification of rPTP2E suggests the existence of a subfamily of band 4.1 domain-containing PTPs which may play an 
important role in signalling pathway and control of cytoskeletal integrity. 
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1. Introduction 
Protein-tyrosine phosphatase (PTP) is a rapidly expanding 
family of enzymes which can be divided into two classes: (i) 
transmembrane, receptor-like and (ii) intracellular, cytosolic 
PTPs. Recent advances in the identification of novel PTPs 
indicate that these enzymes do not act as mere negative switches 
of cellular processes or as ‘house-keeping’ enzymes antagoniz- 
ing the action of PTKs; rather, they actively participate in 
nearly every aspect of signal transduction. Since all PTPs iden- 
tified contain a conserved PTP domain it is expected that the 
characteristics of sequences other than the catalytic domain of 
these enzymes probably play a major role in determining their 
specific functions within the cells. Accordingly, the intracellular 
enzymes can be further divided into several subfamilies based 
on the nature of their distinctive non-catalytic regions. One 
such subfamily of intracellular PTPs is made up of enzymes 
possessing two src homology 2 (SH2) domains. Three members 
of the SH2 domain-containing PTPs have been cloned. They 
are PTPlC (also known as SH-PTPl, HCP, or SHP) [l-3], 
PTP2C (also designated as SH-PTP2, Syp, or PTPlD) [4-71, 
and Drosophila corkscrew (csw) [8]. As with other SH2 domain- 
containing proteins, the SH2 domains of these PTPs bind to the 
autophosphorylation sites of tyrosine kinase receptors and 
other tyrosine-phosphorylated proteins, thus participating in 
signal transduction pathways [6,7,9, lo]. Another emerging sub- 
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family of intracellular PTPs is composed of proteins possessing 
a large non-catalytic segment with homology to the N-terminal 
portion of the cytoskeleton-associated proteins of the band 4.1 
family, which includes ezrin [l 11, radixin [12], and moesin [ 131. 
This subfamily of PTPs is expanding and currently includes 
PTPHl [14], PTP-MEG1 [15], and hPTPlE, also known as 
PTP-BAS and PTPLl [16-181. In this report, we describe the 
identification from rat tissues of a fourth member of this band 
4.1 domain-containing PTP subfamily, a cytosolic PTP which 
we designated as rPTP2E. 
2. Materials and methads 
2.1. Isolation of rPTP2E cDNA 
In order to obtain novel PTP cDNA sequences, the following strategy 
was employed. RNA prepared from mouse embryos (4 days) was sub- 
jected to RT-PCR using a pair of degenerate oligonucleotides, derived 
from two well-conserved regions of known PTPs. The sequence of the 
first oligonucleotide corresponded to the amino acid sequence 
DFWRMV/IWE and the second to the amino acid sequence WPDFI 
HGVP. The resulting RT-PCR fragments were cloned into the pGEM- 
T vector (Promega) to facilitate further manipulation. In order to elim- 
inate known PTP sequences, the RT-PCR fragments were re-amplified 
from individual transformed bacterial colonies, separated on an aga- 
rose gel, and transferred to a nylon membrane by Southern blotting. 
The membrane was hybridized with a mixture of DNA probes consist- 
ing of the catalytic domains of LAR(Dl), LAR(DZ), HPTPa, HPTPG, 
HPTP&, PTPlC and several other known PTPs [1,19,20]. The blots were 
then subjected to high stringency washes. The PCR fragments which 
exhibited a weak or no signal were analyzed by DNA sequencing. Those 
fragments which contained novel PTP sequences were used as probes 
to screen the corresponding overlapping clones in a rat cDNA library 
(Stratagene) made from decidual tissue, or in a mouse embryo cDNA 
library. DNA sequencing was determined on both strands by the dide- 
oxy chain-termination method (T7 Sequencing Kit; Pharmacia Inc.). 
The anchor PCR was performed as described [16]. 
2.2. RNA isolation and Northern blot analysis 
Total RNA or poly(A)’ RNA was purified from rat tissues using the 
standard guanidine isothiocyanateiacid-phenol method. Approxi- 
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mately 20 ,ug total RNA (or 6 pg of poly(A)’ RNA) from each tissue 
was separated on a 1% (w/v) agarose-formaldehyde g l by electropho- 
resis and blotted onto a nylon filter. The membrane was subsequently 
hybridized with ‘*P-labelled probes corresponding to the catalytic do- 
main of rPTP2E cDNA fragment. Hybridized mRNA was detected by 
autoradiography. 
2.3. Expression in Escherichia coli and phosphatase assay 
A segment encoding the entire catalytic domain of rPTP2E (amino 
acids 8341175) was amplified by PCR and cloned in-frame into the 
bacterial expression vector PET-3c [21]. The resultant plasmid, desig- 
nated pdPTP2E, was used to transform Escherichia coli BL21 (DE3) 
cells. Expression of recombinant enzyme was carried out as described 
[l] except hat cells were cultured at 22°C and induced by 50,~M IPTG 
for 24 h. The recombinant protein consists of 351 amino acids in which 
the first 9 residues were derived from the vector. 
For the phosphatase assay, the substrate, RCM-lysozyme (Life Tech- 
nologies Inc.), was tyrosine-phosphorylated with [y-“P]ATP using 
p60”“‘” (Oncogene Science) following the manufacturer’s instructions. 
The induced bacteria were centrifuged, resuspended in 25 mM Tris- 
HCl, pH 8.0, and 5 mM DTT, and lysed by sonication. Activity assay 
was performed by incubating crude bacterial lysates in 25 mM, pH 8.0, 
5 mM DTT, 15 mM NaCl, 10 &ml BSA, 8 mM MgCl, and 0.77 PM 
‘*P-labelled RCM-lysozyme at 30°C for 30 min. The reaction was 
stopped by addition of 400 ~1 of charcoal mixture (0.9 M HCl, 90 mM 
sodium nvronhosDhate. 2 mM NaH,PO,. 4% w/v Norit A). After 
vortexi&-and ce&ifugation, the released radioactive P, present in the 
supernatant was determined by scintillation counting. Protein determi- 
nation was performed by a standard Bradford assay. 
3. Results 
3.1. Isolation and characterization of rPTP2E cDNA 
In order to identify novel PTP sequences in mRNA prepara- 
tions, RT-PCR was performed using a pair of degenerate 
oligonucleotide primers designed from the conserved regions of 
the catalytic domains of known tyrosine phosphatases. The 
amplified PCR fragments, about 250 bp in length, were cloned 
into the pGEM-T vector (Promega). The putative PTP se- 
quences were individually re-amplified from each clone with T7 
and Sp6 primers flanking the inserts, and analyzed by Southern 
blotting. The membranes were hybridized at high stringency 
with a mixture of probes derived from the catalytic domains of 
previously identified PTP cDNAs. Clones displaying weak or 
no hybridization signal were analyzed by DNA sequencing. 
Out of approximately one thousand primary clones, a few ap- 
peared to encode novel PTP sequences. One such identified 
PCR fragment was used to screen a rat cDNA library. 
Several overlapping clones were obtained which constituted 
a cDNA sequence of 5,543 nucleotides. The cDNA sequence 
contains a single open reading frame starting from nucleotide 
266, predicting a protein of 1175 amino acid residues which we 
termed rPTP2E (Fig. 1A). The absence of an N-terminal signal 
peptide and putative transmembrane sequence suggests that 
rPTP2E is a cytosolic PTP. The phosphatase domain, consist- 
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ing of approximately 240 amino acid residues, is located at the 
extreme carboxyl end of the protein. This domain shares about 
40% amino acid sequence identity with the catalytic domains 
of several known PTPs. The large middle portion of rPTP2E, 
encompassing amino acid residues 349-916, does not contain 
significant homology to known protein sequences. At the N- 
terminus, a segment of about 350 amino acids displays 25-30% 
identity to the N-terminal portion of the cytoskeletal protein 
family, including moesin [13], ezrin [l 11, radixin [12], merlin 
[22,23] and the protein band 4.1 [24]. This region also shares 
sequence homology with three human tyrosine phosphatases, 
PTPMEGl [15], PTPHl [14] and the recently cloned hPTPlE/ 
PTP-BAWPTPLl [l&18] with 34,30, and 25% identity, respec- 
tively. 
In addition to the clones encoding the 1175 amino acid poly- 
peptide of rPTP2E, a related cDNA clone was also identified 
from the cDNA library. This cDNA was 3064 nucleotides in 
length and differed from the longer cDNA (rPTP2E) in the first 
299 base pairs which were unique to the shorter sequence (Fig. 
1B and Fig. 2). Starting at position 300, the sequence of this 
cDNA clone was identical to that of the longer cDNA clone 
rPTP2E (position 2779 to the end). The first in frame ATG 
initiation codon within this shorter cDNA clone was located at 
nucleotides 304-306 which corresponds to the methionine resi- 
due 840 of the rPTP2E protein (nucleotides 2783-2785 of the 
5.6 kb cDNA). The predicted protein from this 3.1 kb cDNA 
consists of the last 335 amino acid residues of the rPTP2E 
protein, which constitute almost exclusively the catalytic do- 
main. This variant polypeptide was termed rPTP2E 1. To verify 
the presence of the variant rPTP2El transcripts in rat tissues, 
PCR and anchor PCR were performed using reverse-tran- 
scribed rat total RNA with primers specific to rPTP2El (Fig. 
2). Sequencing of both the PCR and anchor PCR products 
confirmed that rPTP2El transcripts were indeed present in rat 
RNA. 
Several mouse cDNA clones homologous to PTP2E were 
also identified from an embryonic mouse cDNA library. Partial 
sequence determination of these clones revealed an amino acid 
sequence identity of over 96% between the two species (data not 
shown). 
3.2. Expression of rPTP2E in rat tissues 
The expression of rPTP2E in rat tissues was assessed by 
Northern blot analysis (Fig. 3). Total RNA prepared from 
various rat tissues was hybridized to a cDNA probe corre- 
sponding to the catalytic domain. Two major species of 
mRNA, 3.1 kb and 5.6 kb, were readily detected in most tissues 
with the exception of the spleen. The sizes of these two major 
species of mRNA were consistent with that of rPTP2E and 
rPTP2El cDNA clones described above. The distributions of 
Fig. 1. Nucleotide and deduced amino acid sequence of the rPTP2E and rPTP2El cDNAs. (A) rPTP2E. The nucleotides are numbered from the 
5’ end of the 5.6 kb cDNA clone. The first ATG codon in the open reading frame at position 266268 and another ATG codon at position 2783-2785 
which is used as the initiation codon of its variant rPTP2El (see Fig. lB), are shown in bold letters. The arrowhead indicates the position from which 
the nucleotide sequence is identical to that of its variant rPTP2El (see Fig. 1B). The band 4.1 domain is marked by the shaded area (amino acid 
residues 9-348). The catalytic domain is presented in bold letters on a shaded background (amino acid residues 917-1175). (B) The 5’ non-coding 
nucleotide sequence of rPTP2El. The nucleotides are numbered from the 5’ end of the 3.1 kb cDNA clone. The first ATG codon in the open reading 
frame at position 304306 is marked in bold letters. The number (840) in parentheses refers to amino acid residue Met-840 of rPTP2E protein in 
A. The dashed lines following both the nucleotide and amino acid sequences represent their identity to the rPTP2E cDNA clone (A). The arrowhead 
indicates the position from which the nucleotide sequence is identical to that of rPTP2E (starting from position 2779 in A). 
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Fig. 2. Schematic omparison of the structures of rPTP2E and rPTP2El. The boxes represent the coding regions; the thinner boxes represent 5’ and 
3’ untranslated regions. The catalytic domain, the band 4.1 domain, and the numbering of the nucleotides and amino acid residues in each clone 
are indicated. Arrows indicate the positions of the primers designed for RT-PCR of rF’TP2E and rPTP2El segments, respectively. Inset: RT-PCR 
results. Lane 1, from rPTP2E (PCRl); Lane 2, from rPTP2El (PCRZ). 
the species, and the expression level of mRNA was variable 
from one tissue to another. Both species of mRNA were present 
in heart, muscle and adrenal gland with the strongest signal for 
both species in adrenal gland. Only the short form (3.1 kb) was 
expressed in the ovary and testis, whereas brain, uterus and 
lung expressed only the long form (5.6 kb). In the liver, in 
addition to the long form (5.6 kb species), a 2.4 kb mRNA also 
strongly hybridized to the probe. However, the corresponding 
cDNA clones to the 2.4 kb mRNA species have not been 
identified yet. 
3.3. Expression of the recombinant enzyme 
To investigate whether the cDNA of PTPZE encodes a func- 
kb 
Fig. 3. Analysis of rPTP2E mRNA abundance by Northern blotting. 
RNAs were prepared from various rat tissues. Each lane contains 20 
pg of total RNA. The expressed mRNA level of rPTP2E in the tissues 
was examined by hybridization with a 275 bp fragment probe prepared 
from the catalytic domain (nucleotides 32063475) of rPTP2E (A). A 
p-actin probe was used as a control to check the integrity of the mRNA 
(B). The numbers on the left refer to the size of RNA markers given 
in kb. 
tional enzyme, the C-terminal portion of PTP2E, which con- 
tains the entire catalytic domain of the phosphatase, was cloned 
into the bacterial expression vector PET-3c. The recombinant 
protein expressed in induced E. coli cells, although accounting 
for about 15% of total bacterial cellular proteins (Fig. 4 inset, 
lane +), was found to be nearly totally insoluble. The 39 kDa 
band of the recombinant protein observed in induced cells 
could not be detected in the supematants by Coomassie blue- 
stained SDS-PAGE (data not shown). However, the superna- 
tants prepared from the induced cells harbouring pdPTP2E 
plasmid displayed a more than lo-fold increase in tyrosine 
phosphatase activity in comparison with that resulting from 
cells transformed by the vector alone (Fig. 4) when labelled 
RCM-lysozyme was used as substrate. The activity of the re- 
combinant enzyme toward this substrate, although relatively 
low, was nearly completely inhibited by 1 mM sodium vana- 
date, a characteristic of protein tyrosine phosphatases (data not 
shown). The recombinant protein did not show an apparent 
activity towardp-nitrophenyl phosphate, an artificial, non-nat- 
ural substrate for protein tyrosine phosphatases. These results 
indicate that PTP2E may specifically interact with its physio- 
logical substrate(s). 
4. Discussion 
To identify novel PTP sequences we have used known PTP 
probes hybridized to cloned RT-PCR fragments on Southern 
blots. Out of several hundred primary candidates, one PCR 
fragment did not hybridize to the probes used. Nucleotide se- 
quence analysis confirmed that this PCR fragment corre- 
sponded to a new PTP sequence. Screening a rat cDNA library 
with this PCR fragment as a probe resulted in the identification 
of several overlapping clones encoding a new soluble phosphat- 
ase which we termed rPTP2E. A variant of rPTP2E, termed 
rPTP2E1, was also identified. rPTP2El is a truncated version 
of rPTPlE containing almost exclusively the phosphatase cata- 
lytic domain of rPTP2E. This variant appears to be produced 
by the transcription of the same gene, 5’ but from a different 
promoter, and a new site of initiation, since the 5’ non-coding 
region of the cDNA is completely different from that encoding 
the larger form of the protein. Northern blot analysis revealed 
the presence of three rPTP2E RNA transcripts in rat tissues. 
The cDNA clones of rPTP2E and rPTP2El correspond to the 
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species of 5.6 kb and 3.1 kb mRNA, respectively. cDNA clones 
corresponding to the 2.4 kb transcript observed in the liver were 
not identified in the cDNA libraries screened. 
The N-terminal portion of rPTP2E consisting of approxi- 
mately 350 amino acid residues, displays homology to the band 
4.1 protein family which includes ezrin [ 111, radixin [12], moesin 
[13], talin [25], merlin [22-231 and three PTPs, PTPHl [14], 
PTPMEGl [15] and the recently cloned hPTPlE/PTP-BAS/ 
PTPLl [l&18]. The importance of this protein family has been 
emphasized recently with the finding that the tumor suppressor 
neurofibromatosis type 2 gene (NF2) encodes a cytoplasmic 
protein with striking sequence similarity to several members of 
this protein family [22,23]. 
The subcellular localization of some of these proteins has 
been studied. It has been shown that several members of the 
band 4.1 domain-containing proteins co-localize with the corti- 
cal actin cytoskeleton where they interact with both the cell 
membrane and the actin cytoskeleton [26]. The presence of a 
highly homologous domain in rPTP2E suggests that this phos- 
phatase, as well as the other members of this subfamily of 
tyrosine phosphatases, are most likely targeted to the interface 
between the plasma membrane and the cytoskeleton, where 
they may regulate cellular signal transduction pathways 
through dephosphorylation of other proteins present within 
this subcellular compartment. 
During the review of this paper, the sequence of a related 
protein, PTPDl, was reported by Msller et al. [27]. Amino acid 
sequence comparison revealed that rPTP2E and human PTPD 1 
share a great deal of sequence identity, particularly within their 
N-terminal band 4.1 domains and their C-terminal catalytic 
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Fig. 4. Phosphatase activity of recombinant PTP2E expressed in bacte- 
ria. Phosphatase activity, expressed as increased release of P, in fmol 
lmin from 32P-labelled RCM-lysozyme, is presented as a function of the 
amount of bacterial extracts. l , cells transformed with pdPTP2E; o, 
cells transformed with PET-3c vector alone. The inset shows a Coomas- 
sie blue-stained gel (SDS-PAGE) of E. coli cells transformed with 
pdPTP2E plasmid. Lane +, IPTG induced cells; lane -, non-induced 
cells. The 39 kDa band corresponding to the recombinant enzyme is 
indicated by the arrow. 
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Fig. 5. (A) Schematic omparison of the sequence homology of rPTP2E 
and hPTPD1. The band 4.1 domains, the catalytic domains and the 
middle portions are represented and the percentage of identity between 
the segments of the two proteins is indicated. Numbers refer to the 
positions of the amino acid residues of rPTP2E. (B) Detailed sequence 
comparison of amino acid residues 351-906 of rPTP2E with the homol- 
ogous segment of hPTPD1. The amino acid sequences of the middle 
portion of rPTP2E and hPTPD1 are aligned. Only the residues of 
hPTPD1 differing from those of rPTP2E are presented. The minus 
symbol indicates a missing residue in hPTPD1. 
domains which share 95% and 97% sequence identity, respec- 
tively (Fig. 5A). There are 141 amino acid differences between 
the sequences of the two proteins. However, a large proportion 
of these differences is located in the middle region of the protein 
where the two polypeptides have an overall 80% sequence iden- 
tity. Interestingly, there is a segment in the middle portion of 
the two proteins (amino acid residues 72&753 of rPTP2E) 
where the two proteins display entirely different sequences (Fig. 
5B). At present it is unknown whether the sequence difference 
in this region of the two proteins is the result of alternative 
splicing of exons within the rat and human genes. Nevertheless, 
the sequence differences observed between rPTP2E and human 
PTPDl may imply the existence of yet further variation within 
the subfamily of the band 4.1 domain-containing PTPs. 
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